Equillium acquires Bioniz Therapeutics to expand immunomodulatory drug pipeline

Equillium, a Nasdaq-listed biotech company, has acquired Bioniz Therapeutics in a deal worth up to around $329 million, in a move to considerably expand its ... Read More